Aclaris Therapeutics Inc (ACRS)
1.23
0.00 (0.00%)
USD |
NASDAQ |
Apr 18, 16:00
1.22
-0.01
(-0.81%)
After-Hours: 06:45
Aclaris Therapeutics Research and Development Expense (Quarterly): 26.65M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 26.65M |
| September 30, 2023 | 23.88M |
| June 30, 2023 | 25.28M |
| March 31, 2023 | 22.59M |
| December 31, 2022 | 21.07M |
| September 30, 2022 | 23.66M |
| June 30, 2022 | 18.78M |
| March 31, 2022 | 14.31M |
| December 31, 2021 | 14.10M |
| September 30, 2021 | 13.98M |
| June 30, 2021 | 7.897M |
| March 31, 2021 | 7.838M |
| December 31, 2020 | 8.956M |
| September 30, 2020 | 6.24M |
| June 30, 2020 | 6.466M |
| March 31, 2020 | 7.677M |
| December 31, 2019 | 10.83M |
| September 30, 2019 | 16.18M |
| June 30, 2019 | 17.52M |
| Date | Value |
|---|---|
| March 31, 2019 | 19.64M |
| December 31, 2018 | 19.36M |
| September 30, 2018 | 15.19M |
| June 30, 2018 | 13.98M |
| March 31, 2018 | 13.61M |
| December 31, 2017 | 9.203M |
| September 30, 2017 | 10.86M |
| June 30, 2017 | 7.965M |
| March 31, 2017 | 7.772M |
| December 31, 2016 | 6.943M |
| September 30, 2016 | 7.162M |
| June 30, 2016 | 9.836M |
| March 31, 2016 | 9.535M |
| December 31, 2015 | 2.402M |
| September 30, 2015 | 9.407M |
| June 30, 2015 | 1.793M |
| March 31, 2015 | 1.737M |
| December 31, 2014 | 2.054M |
| September 30, 2014 | 2.097M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.24M
Minimum
Sep 2020
26.65M
Maximum
Dec 2023
15.47M
Average
14.31M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Aldeyra Therapeutics Inc | 4.298M |
| Allakos Inc | 53.80M |
| Regeneron Pharmaceuticals Inc | 1.177B |
| Puma Biotechnology Inc | 12.87M |
| CytomX Therapeutics Inc | 19.39M |